Oncological particulate drug system with different sizes and layer compositions

Control-released particulate system has been developed in recent decades to improve efficiency of drug delivery. Fabrication of polymeric particulate system has been developed with different methods, forms, and layer systems. Emulsion solvent evaporation method is simple and affordable method to rep...

Full description

Saved in:
Bibliographic Details
Main Author: Martin Mardjuki
Other Authors: Loo Say Chye Joachim
Format: Final Year Project
Language:English
Published: 2015
Subjects:
Online Access:http://hdl.handle.net/10356/62997
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:Control-released particulate system has been developed in recent decades to improve efficiency of drug delivery. Fabrication of polymeric particulate system has been developed with different methods, forms, and layer systems. Emulsion solvent evaporation method is simple and affordable method to replicate samples in laboratory. Emulsion solvent evaporation method was adjusted in this project into three adjustments. The adjustments were to fabricate three size categories of particulate systems, namely nanoparticles (100 nm - 500 nm), (single-layer) microparticles (500 nm - 5 μm), and double-layer microparticles (50 μm - 100 μm). Samples were analysed using SEM, UV-vis spectroscopy and HPLC to study their morphologies and drug release profiles. Nanoparticles fabricated were agglomerated and had burst release of the drug. Microparticles fabricated had wide range of size distribution thus small amount of agglomeration occurred on the nano-sized range (500 nm - 1 μm) in the sample. Despite of agglomeration, microparticles were shown to have sustained release profile. Lastly, double-layer microparticles averaged at 80 μm was fabricated. PTX was released faster than DOX and burst released, and it is not following the release order according to their position in the particle. After modification to the second on-going release study, drugs were sustained release where DOX was released faster than PTX.